Alnylam Pharmaceuticalsvs.Biogen
ALNY vs BIIB · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.4× larger than Biogen by market cap; Biogen trades at the lower P/E (21.3 vs 69.1); year to date, Biogen leads (+13.2% vs −24.9%).
Side by side
| ALNY | BIIB | |
|---|---|---|
| Market cap | $39.9B | $29.3B |
| Price | $298.76 | $199.15 |
| Today | −4.5% | +0.1% |
| Return YTD | −24.9% | +13.2% |
| Return 1Y | −7.4% | +47.2% |
| P/E | 69.1 | 21.3 |
| P/S | 9.3 | 2.9 |
| P/B | 37.1 | 1.6 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →More comparisons in Biotech & innovation
See where ALNY and BIIB sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →